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Available online 22 October 2015Prostate cancer, the most commonly diagnosed cancer among
males, has multiple treatment options. Robot-assisted laparoscopic
prostatectomy (RALP) is increasingly used, but it remains uncertain
whether its potential beneﬁts offset its higher costs. Since 2010,
new agents for metastatic castration-resistant prostate cancer
(mCRPC) have been approved. However, as these treatments are
considered expensive compared with older conventional medica-
tions, their use is often limited by economic constraints. The global
incidence of prostate cancer is expected to increase. For this reason,
the rising medical costs associated with treatments should be
considered.
In Japan, the costs of medical care provided under the public
Healthcare Insurance System are paid mainly through insurance
premiums and tax revenues. The national health expenditure has
been rapidly increasing and is currently estimated at $400 billion a
year. Thus, the evaluation of healthcare to provide care for patients
more efﬁciently is important. Many countries already incorporate
health economics as part of their public healthcare system.
Both cost and effectiveness are important factors for evalu-
ating the efﬁciency of healthcare.1 Efﬁciency is measured through
the analysis of cost versus effectiveness. Cost-effectiveness
analysis is basically examined by the incremental cost-
effectiveness ratio (ICER).2 An appropriate indicator of effective-
ness in the cost-effectiveness analysis of healthcare depends on
the disease and the types of treatment intervention. Quality-
adjusted life year (QALY), an indicator to evaluate efﬁciency
taking into account both duration of life and quality of life, can be
used in the analyses of various diseases and treatment in-
terventions.1,2 Many countries adopt QALY as part of their eco-
nomic evaluation for policy decisions with analysts selecting the
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p2287-8882 e2287-903XThe application of the results of an economic evaluation com-
prises three steps: assessment, appraisal, and decision-making by
health administrative agencies.2 The term “assessment” refers to
the analyses of the efﬁcacy, safety, and cost-effectiveness of a
healthcare technology by a method scientiﬁcally justiﬁed as
possible. “Appraisal” refers to the interpretation of these results as
well as the comprehensive evaluation of factors such as ethical and
social impacts.1
Applying this economic evaluation, the cost of radical treat-
ments for localised prostate cancer range from $1,761/QALY
(RALP for low-risk) to $3,765/QALY (RALP for high-risk).3 RALP
was, on average, $2,175 more expensive than laparoscopic pros-
tatectomy but there was an effective gain of 0.08 for QALY.4 Thus,
the ICER was $28,230/QALY, making this an immensely costly
treatment.
Based on the cost-effectiveness analysis of treatments for
advanced cancer, the cost per survival ﬁgure for mCRPC are esti-
mated at $206/day (generic $100/day) with docetaxel, $256/day
with abiraterone (post-docetaxel), $310/day with enzalutamide
(post-docetaxel), $757/day with cabazitaxel, and $756/day with
sipuleucel-T. Taking into account survival adjustments necessary to
match placebo groups, abiraterone was found to be the most cost-
effective mCRPC treatment in a study conducted in the United
States ($123,400/QALY with abiraterone vs. $154,300/QALY with
enzalutamide vs. $163,200/QALY with cabazitaxel).5
Denosumab showed superior efﬁcacy in delaying ﬁrst and
subsequent skeletal-related events (SREs) compared with zole-
dronic acid. However, in a United States study it was demonstrated
that the estimated incremental total direct cost per SRE avoided
with the use of denosumab instead of zoledronic acid was $51,319
for 3 years. From a payer's perspective, denosumab may be a more
costly alternative to zoledronic acid.6
Since considerable uncertainty persists in the absence of
directly comparative randomised data in these analyses, further
analyses should examine comparative economic evaluation across
each treatment. In order to reduce national health expenditure, we
suggest the introduction of a ‘reimbursement system’, with stra-
tegies such as price reduction through agreements with companies,
payment by companies for cost of longer-than-expected period,
rebate of sales, and reapplication of beneﬁts. These concepts are
applied by the National Institute of Health and Care Excellence in
Conference Abstract / The healthcare economics of medicationS8the United Kingdom and the Pharmaceutical Beneﬁts Advisory
Committee in Australia.
Conﬂicts of interest
SH received scientiﬁc grants from Astellas, Astrazeneca and
Takeda, honorarium from Astellas, Astrazeneca, Sanoﬁ and Takeda.
Key references
1. Fukuda T. An overview of the methods of economic evaluation in health care.
J Natl Inst Public Health. 2013;62:584e9 (in Japanese).
2. Igarashi A. Economic evaluation in medicines. J Natl Inst Public Health. 2013;62:
605e12 (in Japanese).3. Cooperberg MR, Ramakrishna NR, Duff SB, Hughes KE, Sadownik S, Smith JA,
et al. Primary treatments for clinically localized prostate cancer: a comprehen-
sive lifetime cost-utility analysis. BJU Int. 2013;111:437e50.
4. Close A, Robertson C, Rushton S, Shirley M, Vale L, Ramsay C, et al. Comparative
Cost-effectiveness of Robot-assisted and Standard Laparoscopic Prostatectomy
as Alternatives to Open Radical Prostatectomy for Treatment of Men with
Localised Prostate Cancer: A Health Technology Assessment from the Perspec-
tive of the UK National Health Service. Eur Urol. 2013;64:361e9.
5. Wilson L, Tang J, Zhong L, Balani G, Gipson G, Xiang P, et al. New therapeutic
options in metastatic castration-resistant prostate cancer: Can cost-
effectiveness analysis help in treatment decisions? J Oncol Pharm Pract.
2014;20:417e25.
6. Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, et al. Economic Evalu-
ation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory
Prostate Cancer Patients with Bone Metastases. J Manag Care Pharm.
2011;17:621e34.
